Ana I. Velazquez Manana: Who benefits from adjuvant immunotherapy after neoadjuvant chemotherapy plus immunotherapy and surgery

Ana I. Velazquez Manana shared a post on X:

”Exploratory analysis comparing CM816 to CM77T at WCLC24.

Patrick Forde tries to answer a difficult question, who benefits from adjuvant immunotherapy after neoadjuvant chemotherapy plus immunotherapy and surgery?

Suggested benefit for perioperative approach across subgroups, except those with pathological complete response (pCR), and highest difference in programmed death-ligand 1 (PD-L1) less than 1%.”

Source: Ana I. Velazquez Manana/X

Ana Velázquez Mañana is an Assistant Professor of Medicine in the UCSF Division of Hematology/Oncology at Zuckerberg San Francisco General and a thoracic oncologist at the UCSF Helen Diller Family Comprehensive Cancer Center. She serves as Assistant Director of Diversity, Equity, Inclusion, and Accessibility for Trainees of the UCSF Helen Diller Family Comprehensive Cancer Center and co-chairs the UCSF Department of Medicine Fellowship Diversity Committee. Her research, advocacy, and education efforts are focused on promoting and advancing health equity and workforce diversity. 

Patrick Forde is a Professor at The Johns Hopkins University and Co-Director of the Division of Upper Aerodigestive Malignancies at the Sidney Kimmel Comprehensive Cancer Center. He also serves as the Director of the Thoracic Oncology Research Program at the Johns Hopkins University School of Medicine. Dr. Forde’s research focuses on the role of immunotherapy in treating mesothelioma and lung cancer, and his work has led to the initiation of several ongoing phase 3 clinical trials.